Advances in Cancer Research

Erscheinungsjahr 2016
ISBN: 978-0-12-804789-7
Verlag: William Andrew Publishing

Buch, Englisch, 312 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 680 g

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research, presenting outstanding and original reviews on a variety of topics.

Autoren/Hrsg.

Weitere Mitwirkende

Tew, Kenneth D.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung

Inhaltsverzeichnis

1. The Evolving, Multifaceted Roles of Autophagy In CancerJennifer Liu and Jayanta Debnath2. Inhibitors of DNA Methylation, Histone Deacetylation and Histone Demethylation: A Perfect Combination for Cancer TherapyCynthia A. Zahnow, Michael Topper, Meredith Stone, Tracy Murray-Stewart, Huili Li, Stephen B. Baylin, and Robert A. Casero, Jr.3. Emerging Roles of Epigenetic Regulator Sin3 in CancerNidhi Bansal, Gregory David, Eduardo Farias and Samuel Waxman4. PAKs in Human Cancer Progression - From Inception to Therapeutic to Future Oncobiology Rakesh Kumar and Da-Qiang Li5. Sirtuins and the Estrogen Receptor as Regulators of the Mammalian Mitochondrial UPR in Cancer and AgingDoris Germain6. Keratinocyte Carcinoma as a Marker of a High Cancer-Risk PhenotypeJames Small, Virginia Barton, Brett Peterson and Anthony J. Alberg

Über Autor(innen)

Tew, Kenneth D.
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.